tofacitinib

P2, N=8, Active, not recruiting, The First Affiliated Hospital of Xiamen University

P2, N=120, Recruiting, Peking University People's Hospital; Hebei Fitness Biotechnology Co., Ltd.

P=N/A, N=40, Recruiting, Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University

P=N/A, N=10, Completed, University Hospital, Lille | Terminated --> Completed

After the diagnosis of MDA-5 DM, she was treated with glucocorticoids (GC), followed by rituximab and triple therapy (cyclosporin, cyclophosphamide, and GC); however, she did not improve and multiple adverse effects occurred. The patient then started tofacitinib (TOF) and improved...TOF was stopped, and the patient started oral acyclovir and intravenous and intravitreal ganciclovir, which was later changed to maintenance therapy with oral valganciclovir. Cyclical intravenous immunoglobulin (IVIG) administration was started, resulting in an overall improvement in disease activity associated with MDA-5 DM. This case underscores the uncommon link between CMV retinitis in a non-HIV patient and HSV anterior uveitis in a patient undergoing immunosuppressive therapy and the challenge of treating MDA-5 DM with IVIG, which led to favorable results.

P3, N=135, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

UPA was found to be non-inferior to TOFA in improving 6-month lung transplantation-free survival among patients with MDA5+DM-ILD, with comparable safety.

Tofacitinib provided early and sustained improvement of disease signs and symptoms in patients with RA in Canada. Safety was consistent with the RA clinical program and the established tofacitinib clinical profile. Results were consistent with the interim analysis.

We describe four men (aged 44-65 years) with long-standing, severe CAD unresponsive to multiple systemic treatments, including immunosuppressants, dupilumab, and tofacitinib. Treatment was well tolerated, with only mild acneiform eruption and transient hypertriglyceridaemia in one case. These findings suggest that selective JAK1 inhibition may represent a therapeutic option in severe, treatment-refractory CAD.

In human PBMC assays and preclinical models of acute and chronic inflammation, ELN28-135-01 achieved superior pharmacodynamic control compared with nonconjugated anti-TNF-α comparators while minimizing exposure to free tofacitinib. These findings support soluble cytokine-directed soloMERⓇ drug conjugates as a strategy for site-restricted dual-node inflammatory pathway modulation with the potential to improve efficacy and reduce JAK inhibitor toxicities.

The pan-JAK inhibitor tofacitinib (TOF) has emerged as an effective therapeutic option for inducing and maintaining clinical remission in moderate-to-severe UC. Comprehensive in vitro and in vivo assessments of mEXOs@TOF confirmed the enhanced anti-inflammatory treatment on UC, with no detectable adverse effects. Collectively, the mEXOs@TOF nanodelivery system represents a targeted therapeutic strategy for improving UC treatment.

P3, N=42, Recruiting, Assistance Publique - Hôpitaux de Paris | Suspended --> Recruiting